MX2020002053A - [6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo. - Google Patents

[6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo.

Info

Publication number
MX2020002053A
MX2020002053A MX2020002053A MX2020002053A MX2020002053A MX 2020002053 A MX2020002053 A MX 2020002053A MX 2020002053 A MX2020002053 A MX 2020002053A MX 2020002053 A MX2020002053 A MX 2020002053A MX 2020002053 A MX2020002053 A MX 2020002053A
Authority
MX
Mexico
Prior art keywords
mthf
alternative
based chemotherapy
folate
fluorouracil
Prior art date
Application number
MX2020002053A
Other languages
English (en)
Inventor
Anders Vedin
Per Lennart Lindberg
Gunnel Elisabeth Sundén
Bengt Gustavsson
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Publication of MX2020002053A publication Critical patent/MX2020002053A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al tratamiento de tumores sólidos en seres humanos tales como cáncer, especialmente cáncer colorrectal (CRC), que implica administrar el adyuvante de folato diastereoméricamente puro [6R]-5,10-metilentetrahidrofolato en quimioterapia basada en 5-fluorouracilo (5-FU).
MX2020002053A 2017-08-24 2018-01-05 [6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo. MX2020002053A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17187684.0A EP3446704A1 (en) 2017-08-24 2017-08-24 [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy
PCT/EP2018/050273 WO2019037898A1 (en) 2017-08-24 2018-01-05 [6R] -MTHF - EFFECTIVE ALTERNATIVE TO FOLATE IN CHEMOTHERAPY BASED ON 5-FLUOROURACILE

Publications (1)

Publication Number Publication Date
MX2020002053A true MX2020002053A (es) 2020-12-11

Family

ID=59702573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002053A MX2020002053A (es) 2017-08-24 2018-01-05 [6r]-mthf - una alternativa eficaz al folato en quimioterapia basada en 5-fluorouracilo.

Country Status (19)

Country Link
US (2) US11013744B2 (es)
EP (3) EP3446704A1 (es)
JP (2) JP7356411B2 (es)
KR (1) KR102216031B1 (es)
CN (1) CN110290802A (es)
AU (1) AU2018320069A1 (es)
BR (1) BR112020003585A2 (es)
CA (2) CA3073555C (es)
DK (1) DK3446705T3 (es)
ES (1) ES2901621T3 (es)
HU (1) HUE057332T2 (es)
IL (1) IL272874B2 (es)
MX (1) MX2020002053A (es)
PL (1) PL3446705T3 (es)
PT (1) PT3446705T (es)
RU (1) RU2763934C2 (es)
SG (2) SG11202001372TA (es)
TW (1) TWI752147B (es)
WO (1) WO2019037898A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376658A (en) 1990-05-11 1994-12-27 University Of Southern California 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1942189A (zh) * 2004-04-02 2007-04-04 阿德文特克斯药物有限公司 5,10－亚甲基四氢叶酸在癌症治疗中的用途
US20070280944A1 (en) * 2004-04-02 2007-12-06 Adventrx Pharmaceuticals, Inc. Use of 5,10-Methylene Tetrahydrofolate for the Treatment of Cancer
KR20070019725A (ko) 2004-04-02 2007-02-15 어드벤트륵스 파마슈티칼스, 인크. 암치료에 사용되는 5,10-메틸렌 테트라하이드로폴레이트의용도
US20090221594A1 (en) 2005-12-02 2009-09-03 Chen Andrew X Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolate
KR20090074202A (ko) 2006-09-18 2009-07-06 베링거 인겔하임 인터내셔날 게엠베하 Ｅｇｆｒ 돌연변이를 갖는 암을 치료하는 방법
WO2008109349A1 (en) 2007-03-06 2008-09-12 Adventrx Pharmaceuticals, Inc. Improved regimen for treating cancer with 5-fluorouracil, 5,10-methylenetetrahydrofolate and capecitabine
EP2335074B1 (en) 2008-09-26 2013-03-20 Institut de Cancérologie de l'Ouest (I.C.O) Individual 5-fluorouracile dose optimization in folfox treatment
JP2013523843A (ja) 2010-04-15 2013-06-17 ベジェニクス ピーティーワイ リミテッド Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療
EP2617421A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
EP2617422A1 (en) 2012-01-20 2013-07-24 Isofol Medical AB Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
EP3305318A1 (en) 2016-10-05 2018-04-11 Isofol Medical AB [6r]-5,10-methylenetetrahydrofolate in 5-fluorouracil based chemotherapy

Also Published As

Publication number Publication date
RU2763934C2 (ru) 2022-01-11
HUE057332T2 (hu) 2022-05-28
EP3446705B1 (en) 2021-09-22
PL3446705T3 (pl) 2022-05-23
CA3073555A1 (en) 2019-02-28
JP2020531490A (ja) 2020-11-05
RU2020109130A (ru) 2021-09-24
DK3446705T3 (da) 2021-12-13
EP3446704A1 (en) 2019-02-27
BR112020003585A2 (pt) 2020-09-01
IL272874B1 (en) 2023-12-01
KR102216031B1 (ko) 2021-02-16
IL272874B2 (en) 2024-04-01
TWI752147B (zh) 2022-01-11
JP2019038797A (ja) 2019-03-14
IL272874A (en) 2020-04-30
RU2020109130A3 (es) 2021-09-24
JP7356411B2 (ja) 2023-10-04
EP3446705A1 (en) 2019-02-27
US20210401842A1 (en) 2021-12-30
US20190060316A1 (en) 2019-02-28
SG10201800195XA (en) 2019-03-28
AU2018320069A1 (en) 2020-03-05
KR20190022270A (ko) 2019-03-06
SG11202001372TA (en) 2020-03-30
WO2019037898A1 (en) 2019-02-28
US11013744B2 (en) 2021-05-25
CN110290802A (zh) 2019-09-27
EP3672623A1 (en) 2020-07-01
CA3073555C (en) 2023-01-10
ES2901621T3 (es) 2022-03-23
CA2991357A1 (en) 2019-02-24
TW201912159A (zh) 2019-04-01
PT3446705T (pt) 2021-12-29

Similar Documents

Publication Publication Date Title
PH12019501959A1 (en) Therapeutic rna
MX2023010042A (es) Polinucleotidos moduladores.
EP4339287A3 (en) Modified cells and methods of therapy
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12017502086A1 (en) Cancer treatments
PH12017502002A1 (en) 5`-substituted nucleoside analogs
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2019008032A (es) Combinaciones de cabozantinib y atezolizumab para tratar cancer.
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX2020002075A (es) Administración en bolo múltiple de [6r]-mthf en quimioterapia basada en 5-fluorouracilo.
NZ739133A (en) Cellular targeted active ingredient delivery system
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
WO2012103457A3 (en) Stilbene analogs and methods of treating cancer
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
WO2019023315A3 (en) RAC INHIBITORS
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
AU2017264839A1 (en) 2-Anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers